Group 1 - The sugar substitute concept declined by 0.82%, ranking among the top declines in the concept sector, with companies like Baolingbao, Bailong Chuangyuan, and Chenguang Biotech experiencing significant drops [1][2] - Among the sugar substitute stocks, 8 saw price increases, with Zhonghua International, Luxin Investment, and Xinghu Technology rising by 1.37%, 1.34%, and 1.09% respectively [1][2] - The sugar substitute sector experienced a net outflow of 118 million yuan, with 17 stocks seeing net outflows, and 5 stocks with outflows exceeding 10 million yuan, led by Jinhai Biological with a net outflow of 44.98 million yuan [2][3] Group 2 - The top net inflow stocks in the sugar substitute sector included Jinhai Industrial, Rhine Biological, and Shengquan Group, with net inflows of 16.36 million yuan, 12.29 million yuan, and 5.05 million yuan respectively [2][3] - The outflow leaderboard for the sugar substitute sector featured Jinhai Biological, Yasheng Group, and Baolingbao, with respective outflows of 44.98 million yuan, 25.20 million yuan, and 22.92 million yuan [2][3] - The trading activity in the sugar substitute sector showed varied turnover rates, with Baolingbao at 14.36% and Jinhai Biological at 6.48% [2][3]

证券代码：002688 证券简称：金河生物 公告编号：2025-037 金河生物科技股份有限公司 关于控股股东部分股份解除质押的公告 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份解除质押。具体事项如下： 一、股东股份解除质押基本情况 | 股东名称 | 是否为控股股东 | 本次解除 | 占其所 | 占公司 | 质押开始 | 质押解除日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 或第一大股东及 | 质押股份 | 持股份 | 总股本 | | | | | | 其一致行动人 | 数量 | 比例 | 比例 | 日期 | 期 | | | | | | | | 2022 年 07 | | | | 金河控股 | 是 | 11,400,472 | 4.71% | 1.48% | 月 27 日 | 2025 年 5 月 | 华西证券股 | | | | 6,883,527 | 2.85% | 0.89% | 2023 年 3 | 9 日 | 份有 ...

金河生物（002688）公告，控股股东金河控股近日解除质押1828.4万股，占其所持股份比例7.56%，占 公司总股本比例2.37%。质押开始日期为2022年7月27日和2023年3月14日，质权人为华西证券 （002926）股份有限公司。截至公告披露日，金河控股及其一致行动人累计质押公司股份1.43亿股，占 其所持股份比例51.41%，占公司总股本比例18.57%，不存在平仓风险。 ...

Summary of Conference Call Records Industry Overview - The records focus on the **sugar substitute industry**, specifically the emerging segment of **D-Allulose** as a health-oriented sweetener. The industry is experiencing significant regulatory changes and market opportunities due to new health consumption policies in China [1][2]. Key Points and Arguments - The **Ministry of Commerce and the National Health Commission** of China, along with 12 other departments, issued a notice on promoting health consumption, emphasizing the need to improve healthy dietary consumption levels. This includes guidance for healthcare institutions to provide dietary and exercise advice for patients with hypertension, type 2 diabetes, hyperlipidemia, and obesity [1][2]. - The notice highlights the importance of **food health products**, indicating a high level of attention towards health-oriented sweeteners like **D-Allulose**, which has benefits in lowering blood pressure, reducing lipids, and preventing type 2 diabetes [1][2]. - D-Allulose is on the verge of regulatory approval in China, marking a significant milestone for the domestic sugar substitute market. The product has a long history of approval in other countries, including the United States, Japan, Mexico, Canada, South Korea, and Australia/New Zealand [3]. - D-Allulose is recognized as a **GRAS (Generally Recognized As Safe)** product by FEMA, allowing its use in beverages and dairy products. Canada has also approved it as a natural health product ingredient [3]. - The product not only shares the advantages of **Erythritol** but also promotes the Maillard reaction, lowers blood sugar and lipids, aids liver detoxification, and helps prevent obesity and type 2 diabetes [3]. Company Insights - **Baolingbao** is currently constructing a **30,000-ton D-Allulose project**, which is in the building phase. The company plans to actively promote sales to consumers once D-Allulose is approved for use in China [4]. - **Bailong Chuangyuan** has a **15,000-ton crystalline sugar project** that can produce **5,000 tons of D-Allulose** [4]. Additional Important Content - The records suggest that D-Allulose is emerging as a new star among sweeteners, with no reported side effects. It has similar effects to GLP-1 (glucagon-like peptide-1), which can help combat obesity and diabetes [3]. - The market potential for D-Allulose is vast, as it is expected to replace existing sugar substitutes in beverages and food products, indicating a significant growth trend in the industry [3]. Conclusion - The regulatory environment is becoming increasingly favorable for D-Allulose, positioning it as a key player in the health-oriented sweetener market. Companies like Baolingbao and Bailong Chuangyuan are poised to capitalize on this trend, potentially leading to substantial market growth and investment opportunities in the sector [3][4].

Investment Rating - Industry Rating: Outperform the market (maintained rating) [12] Core Views - The pet sector continues to show high prosperity, driven by domestic substitution and consumption upgrades, leading to a dual increase in volume and price [1][2] - The industry is transitioning from "scale expansion" to "value creation," with leading companies shifting from "manufacturing" to "intelligent manufacturing" through formula innovation and precise demand capture [2][17] - The domestic pet food market remains strong, with a significant increase in sales and exports, indicating robust growth potential for domestic brands [2][17] Summary by Sections Pet Sector - The fifth TOPS Pet Expo in Shanghai showcased over 1,200 exhibitors and 8,000+ brands, reflecting strong growth momentum in the pet industry, with a 43% year-on-year increase in attendance [1][16] - Trends in pet food are shifting towards precision nutrition, with a focus on age-specific feeding and high-end production techniques [1][16] - Key recommended companies in the pet food sector include Guibao Pet, Zhongchong Co., Petty Co., and Lusi Co., with additional recommendations for pet medical and product companies [2][17] Swine Sector - As of May 10, the average price of live pigs was 14.90 yuan/kg, showing a slight decline, with production capacity continuing to grow [3][18] - The industry is facing a potential downturn in profitability due to weak demand and seasonal price declines [3][19] - Recommended companies include leading players such as Wens Foodstuffs and Muyuan Foods, with a focus on core assets [19] Poultry Sector - The white chicken segment is facing uncertainties in breeding imports, with a significant decline in the number of breeding stock updated [20][21] - The yellow chicken segment is expected to benefit from improved consumer demand, with stable prices observed [23] - Recommended companies include Shengnong Development and Lihua Co. for white chicken, and Wens Foodstuffs for yellow chicken [22][23] Planting Sector - The government emphasizes agricultural technology innovation and self-sufficiency in food security, with a focus on biological breeding [25][26] - Recommended companies in the seed sector include Longping High-Tech and Dabeinong, with additional focus on agricultural water-saving technologies [25][26] Feed and Animal Health Sector - Hai Da Group is highlighted for its market share growth and consistent performance in the feed sector [27] - The animal health sector is seeing new opportunities in pet health products, with recommended companies including KQ Bio and Zhongmu Co. [28]

Core Viewpoint - The company has increased the terminal prices in the U.S. market since May 1 of this year to effectively cover the increased tariff costs [1] Group 1 - The price adjustment was implemented to address the impact of rising tariffs on costs [1]

Group 1 - The company has increased the terminal price of its product, Jinmeisu, in the U.S. market as of May 1, 2023 [1] - The price adjustment is aimed at effectively covering the increased tariff costs [1]

证券代码：002688 证券简称：金河生物 公告编号：2025-036 金河生物科技股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份质押。具体事项如下： | 股东 | 是否为控股 股东或第一 | 本次质押数 | 占其所 | 占公司 | 是否 | 是否为 | 质押开 | 质押到 | 质权 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及其 | 量（股） | 持股份 | 总股本 | 为限 | 补充质 | 始日期 | 期日 | 人 | 质押用途 | | | 一致行动人 | | 比例 | 比例 | 售股 | 押 | | | | | | | | | | | | | | | 红塔 | 借款给内蒙 | | 金河 | | | | | | | 2025 ...

華聯律師事務所 Hu a L i a n L a w F ir m 致：金河生物科技股份有限公司 中國北京市朝陽區亮马桥路32號高斓大厦10层 郵編: 100125 電話: 8610-84417811 傳真: 8610-84417306 電郵: hualian@hllf.cn 網址: www.hllf.cn 关于金河生物科技股份有限公司二零二五年第二次临时股东大会的法律意见书 场会议由公司董事长王东晓先生主持。公司通过深圳证券交易所交易系统和深圳 证券交易所互联网投票系统向全体股东提供网络形式投票平台。网络投票的时间 和方式与本次股东大会的会议通知内容一致。 本所律师认为，本次股东大会的召开通知公告在规定时间发布，公司发出召 开股东大会通知的时间、方式及通知内容均符合《公司法》《股东大会规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》（下称 《主板规范运作指引》）和《公司章程》的规定；本次股东大会的召集和召开程 序符合《公司法》《股东大会规则》《主板规范运作指引》和《公司章程》的规 定。 二、本次股东大会出席人员的资格及召集人资格 （一）本次股东大会的出席人员资格 根据中国证监 ...

金河生物科技股份有限公司 2025年第二次临时股东大会决议的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 证券代码：002688 证券简称：金河生物 公告编号：2025-035 (2) 网络投票时间：2025 年 5 月 6 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 6 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为：2025 年 5 月 6 日上午 9:15 至下午 15:00 期间的任意时间。 2、股权登记日：2025 年 4 月 25 日 特别提示： 1、本次股东大会无否决提案的情形。 2、本次股东大会没有涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 金河生物科技股份有限公司（以下简称"公司"）2025 年第二次临时股东 大会通知于 2025 年 4 月 19 日在《上海证券报》、《证券时报》、《证券日报》 《中国证券报》及巨潮资讯网（www.cninfo.com.cn）以公告方式发出。 ...